Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7V9CT)

Drug Name
GM6001 Drug Info
Synonyms
Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup; ILOMASTAT
Indication
Disease Entry ICD 11 Status REF
Corneal ulcer 9A76 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
132519
ChEBI ID
CHEMBL137236
CAS Number
CAS 142880-36-2
TTD Drug ID
DM7V9CT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Matrix metalloproteinase-12 (MMP-12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [9]
FP-025 DMH1NXO Asthma CA23 Phase 1 [10]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [11]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [11]
PMID29130358-Compound-Figure17(11) DMSZA9L N. A. N. A. Patented [11]
AZD1236 DML3RSF Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [12]
V85546 DMLFMSY Inflammation 1A00-CA43.1 Discontinued in Phase 1 [13]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [2]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [14]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-8 (MMP-8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [15]
SC-44463 DMBPNKT N. A. N. A. Terminated [16]
BB-1101 DM7GH5Z Multiple sclerosis 8A40 Terminated [17]
MMI270 DM38N2K Discovery agent N.A. Investigative [18]
IK-862 DMJA4UE Discovery agent N.A. Investigative [19]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [14]
SL422 DM3I2US Discovery agent N.A. Investigative [20]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [14]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN Discovery agent N.A. Investigative [14]
Ro-37-9790 DM83QMZ Discovery agent N.A. Investigative [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-13 (MMP-13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [22]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [23]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [24]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [11]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [11]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [11]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [11]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [11]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [25]
MMI270 DM38N2K Discovery agent N.A. Investigative [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-1 (MMP-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [27]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [28]
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [15]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [23]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [11]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [11]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [29]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [25]
XL784 DMICR39 Diabetic nephropathy GB61.Z Discontinued in Phase 2 [30]
SC-44463 DMBPNKT N. A. N. A. Terminated [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-9 (MMP-9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [32]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [33]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [34]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [35]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [36]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [9]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [11]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [11]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [11]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-14 (MMP-14)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [37]
BT1718 DMTXBUV Solid tumour/cancer 2A00-2F9Z Phase 1/2a [38]
MMI270 DM38N2K Discovery agent N.A. Investigative [39]
IK-862 DMJA4UE Discovery agent N.A. Investigative [19]
SR-973 DMU48OD Discovery agent N.A. Investigative [40]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [14]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [14]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN Discovery agent N.A. Investigative [14]
UK-356618 DM02FGH Discovery agent N.A. Investigative [31]
PMID23631440C29e DMM92IB Discovery agent N.A. Investigative [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-2 (MMP-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [27]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [37]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [28]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [9]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [42]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [11]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [11]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [11]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [11]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-21 (MMP-21)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IK-862 DMJA4UE Discovery agent N.A. Investigative [19]
SR-973 DMU48OD Discovery agent N.A. Investigative [40]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [14]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [14]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN Discovery agent N.A. Investigative [14]
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT Discovery agent N.A. Investigative [4]
N-hydroxy-2,3-bis(phenylsulfonamido)propanamide DMZWIVJ Discovery agent N.A. Investigative [43]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Bacterial Lethal factor (Bact lef)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IQ-DAA DMHP71R Bacillus anthracis infection 1G40 Phase 1 [44]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [45]
MMI270 DM38N2K Discovery agent N.A. Investigative [46]
NSC-622445 DME35CB Discovery agent N.A. Investigative [47]
N-(Sulfanylacetyl)Tyrosylprolylmethioninamide DMWJDYZ Discovery agent N.A. Investigative [2]
N-(3,4-dihydroxybenzyl)oleamide DM67XSW Discovery agent N.A. Investigative [48]
N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea DMT4USP Discovery agent N.A. Investigative [2]
N-hydroxy-4-(oleamidomethyl)benzamide DMUSHZK Discovery agent N.A. Investigative [48]
N-(3,4,5-trihydroxyphenethyl)oleamide DMQ5USA Discovery agent N.A. Investigative [49]
N-oleoyl-dopamine DM1AVCZ Discovery agent N.A. Investigative [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-3 (MMP-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [11]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [25]
PG-530742 DMELXBQ Myocardial infarction BA41-BA43 Discontinued in Phase 2 [50]
Batimastat DM92VRP Idiopathic pulmonary fibrosis CB03.4 Preclinical [51]
SC-44463 DMBPNKT N. A. N. A. Terminated [52]
BB-1101 DM7GH5Z Multiple sclerosis 8A40 Terminated [53]
L-696418 DMV785R N. A. N. A. Terminated [54]
RO-319790 DML3NEU Rheumatoid arthritis FA20 Terminated [55]
MMI270 DM38N2K Discovery agent N.A. Investigative [42]
IK-862 DMJA4UE Discovery agent N.A. Investigative [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Amyloid-beta precursor protein (APP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Selenium DM25CGV N. A. N. A. Approved [57]
Methotrexate DM2TEOL Anterior urethra cancer Approved [58]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [59]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [60]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [61]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [62]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [63]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [64]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor ligand superfamily member 6 (FASLG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [66]
Gefitinib DM15F0X Colon adenocarcinoma Approved [67]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [68]
Epinephrine DM3KJBC Acute asthma CA23 Approved [69]
Quercetin DM3NC4M Obesity 5B81 Approved [70]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [71]
Fructose DM43AN2 Vomiting MD90 Approved [72]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [73]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [74]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [75]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Amyloid beta precursor like protein 2 (APLP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [57]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [76]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [77]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [78]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [79]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [80]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [81]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [82]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [83]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [84]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Lethal factor (Bact lef) TTIQSC1 LEF_BACAN Inhibitor [2]
Matrix metalloproteinase-1 (MMP-1) TTMX39J MMP1_HUMAN Inhibitor [3]
Matrix metalloproteinase-12 (MMP-12) TTXZ0KQ MMP12_HUMAN Inhibitor [4]
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [5]
Matrix metalloproteinase-14 (MMP-14) TTJ4QE7 MMP14_HUMAN Inhibitor [3]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [3]
Matrix metalloproteinase-21 (MMP-21) TTYRF5E MMP21_HUMAN Inhibitor [4]
Matrix metalloproteinase-3 (MMP-3) TTUZ2L5 MMP3_HUMAN Inhibitor [3]
Matrix metalloproteinase-8 (MMP-8) TTGA1IV MMP8_HUMAN Inhibitor [6]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Amyloid beta precursor like protein 2 (APLP2) OTTFE53M APLP2_HUMAN Protein Interaction/Cellular Processes [7]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Protein Interaction/Cellular Processes [7]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Gene/Protein Processing [8]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001387)
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
4 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
5 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
6 Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995).
7 Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J. 2005 Nov;272(22):5808-20. doi: 10.1111/j.1742-4658.2005.04976.x.
8 Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol. 2003 Apr;51(4):284-90. doi: 10.1007/s00280-003-0581-4. Epub 2003 Mar 27.
9 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
10 Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
11 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
12 Clinical pipeline report, company report or official report of AstraZeneca (2009).
13 Clinical pipeline report, company report or official report of Vernalis.
14 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
15 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
16 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50.
17 New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem. 1999 Nov 18;42(23):4890-908.
18 Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 1999 Nov 4;42(22):4547-62.
19 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
20 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
21 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
22 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
23 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
24 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
25 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
26 Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
27 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
28 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
29 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
30 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
31 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
32 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
33 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
34 National Cancer Institute Drug Dictionary (drug id 747683).
35 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
36 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
37 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
38 ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health.
39 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
40 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
41 Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
42 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
43 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
44 Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
45 Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11.
46 The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8.
47 Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44.
48 Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70.
49 Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8.
50 Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
51 Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
52 Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
53 Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
54 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
55 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
56 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
57 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
58 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
59 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
60 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
61 Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
62 Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
63 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
64 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
65 Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
66 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
67 The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
68 NF-B potentiates caspase independent hydrogen peroxide induced cell death. PLoS One. 2011 Feb 15;6(2):e16815. doi: 10.1371/journal.pone.0016815.
69 Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
70 Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep. 2011 Feb;25(2):583-91. doi: 10.3892/or.2010.1097. Epub 2010 Dec 10.
71 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
72 Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
73 Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
74 Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine. Toxicol In Vitro. 2016 Sep;35:66-76. doi: 10.1016/j.tiv.2016.05.013. Epub 2016 May 26.
75 Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol. 2002 Jan;22(1):37-47. doi: 10.1023/a:1014256603539.
76 Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
77 Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
78 The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
79 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
80 PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
81 Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
82 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
83 Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
84 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.